Cargando…
Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations
In the absence of specific therapy, the 15%–20% of breast cancers demonstrating human epidermal growth-factor receptor 2 (HER2) protein overexpression and/or gene amplification are characterized by a more aggressive phenotype and poorer prognosis compared to their HER2-negative counterparts. Trastuz...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037302/ https://www.ncbi.nlm.nih.gov/pubmed/24876795 http://dx.doi.org/10.2147/IJWH.S47357 |